New drug targets genetic weakness in hard-to-treat stomach cancer

NCT ID NCT05117931

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests whether amivantamab can shrink tumors in people with esophagogastric cancer that has a specific genetic change (EGFR or MET amplification). About 25 participants who have already tried at least one other treatment will receive the drug intravenously. The main goal is to see how many patients respond, while also checking for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: amivantamab
What this could lead to: If it works, this could point toward a new treatment option for people with a specific genetic type of esophagogastric cancer that has stopped responding to other therapies.
What could go wrong: This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. The drug may cause side effects like infusion reactions, and it is not yet known if it will shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGOGASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal cancer Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGOGASTRIC CANCER

Contacts and locations

Locations

Massachusetts General Hospital (Data Collection Only)

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Basking Ridge (Limited protocol activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Commack (Limited Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (Limited protocol activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited protocol activities)

Rockville Centre, New York, 11553, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States
University of California, Irvine

Irvine, California, 92697, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.